

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

ANNOUNCEMENT REGARDING COMPLETION OF THE H SHARE FULL CIRCULATION

INTRODUCTION

Reference is made to the announcements (the “**Announcements**”) of Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”) dated November 26, 2021 and February 28, 2022 in relation to the implementation of the full circulation of the H Shares. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE CONVERSION AND LISTING

The Board is pleased to announce that the conversion of the 194,099,746 Domestic Unlisted Shares into the H Shares was completed on March 3, 2022. As disclosed in the announcement of the Company dated February 28, 2022, the Company obtained the Listing Approval on January 18, 2022 and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on March 4, 2022 as scheduled.

The holders of the Converted H Shares who are PRC nationals can only conduct trading of the Converted H Shares subject to the completion of the onshore arrangement procedures as set out in the announcement of the Company dated February 28, 2022. In addition, the relevant H Shares held by the Participating Shareholders are subject to a lock-up period until one year after the listing date of the Company under the PRC laws.

SHARE CAPITAL STRUCTURE

The share capital structure of the Company immediately before and upon completion of the Conversion and Listing is set out below:

Class of shares	Immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	<i>Number of shares</i>	<i>Approximate percentage</i>	<i>Number of shares</i>	<i>Approximate percentage</i>
H Shares	130,519,998	39.27%	324,619,744	97.66%
Domestic Unlisted Shares	201,881,003	60.73%	7,781,257	2.34%
Total	<u>332,401,001</u>	<u>100.00%</u>	<u>332,401,001</u>	<u>100.00%</u>

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, March 3, 2022

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.